



**MIRCERA® (methoxy polyethylene glycol-epoetin beta) Medication
Precertification Request**

Page 1 of 2

(All fields must be completed and legible for Precertification Review.)

Aetna Precertification Notification

Phone: 1-866-752-7021
FAX: 1-888-267-3277

For Medicare Advantage Part B:

Phone: 1-866-503-0857
FAX: 1-844-268-7263

Please indicate: Start of treatment: Start date ____ / ____ / ____
 Continuation of therapy: Date of last treatment ____ / ____ / ____

Precertification Requested By: _____ **Phone:** _____ **Fax:** _____

| | | | |
|---|---|---|--|
| A. PATIENT INFORMATION | | | |
| First Name: _____ | | Last Name: _____ | |
| Address: _____ | | City: _____ | State: _____ ZIP: _____ |
| Home Phone: _____ | Work Phone: _____ | Cell Phone: _____ | |
| DOB: _____ | Allergies: _____ | Email: _____ | |
| Current Weight: _____ lbs or _____ kgs | | Height: _____ inches or _____ cms | |
| B. INSURANCE INFORMATION | | | |
| Aetna Member ID #: _____ | | Does patient have other coverage? <input type="checkbox"/> Yes <input type="checkbox"/> No | |
| Group #: _____ | | If yes, provide ID#: _____ Carrier Name: _____ | |
| Insured: _____ | | Insured: _____ | |
| Medicare: <input type="checkbox"/> Yes <input type="checkbox"/> No If yes, provide ID #: _____ | | Medicaid: <input type="checkbox"/> Yes <input type="checkbox"/> No If yes, provide ID #: _____ | |
| C. PRESCRIBER INFORMATION | | | |
| First Name: _____ | | Last Name: _____ (Check One): <input type="checkbox"/> M.D. <input type="checkbox"/> D.O. <input type="checkbox"/> N.P. <input type="checkbox"/> P.A. | |
| Address: _____ | | City: _____ | State: _____ ZIP: _____ |
| Phone: _____ | Fax: _____ | St Lic #: _____ | NPI #: _____ DEA #: _____ UPIN: _____ |
| Provider Email: _____ | | Office Contact Name: _____ Phone: _____ | |
| Specialty (Check one): <input type="checkbox"/> Oncologist <input type="checkbox"/> Nephrologist <input type="checkbox"/> Other: _____ | | | |
| D. DISPENSING PROVIDER/ADMINISTRATION INFORMATION | | | |
| Place of Administration: | | Dispensing Provider/Pharmacy: <i>Patient Selected choice</i> | |
| <input type="checkbox"/> Self-administered | <input type="checkbox"/> Physician's Office | <input type="checkbox"/> Physician's Office | <input type="checkbox"/> Retail Pharmacy |
| <input type="checkbox"/> Outpatient Infusion Center | Phone: _____ | <input type="checkbox"/> Specialty Pharmacy | <input type="checkbox"/> Other: _____ |
| Center Name: _____ | | Name: _____ | |
| <input type="checkbox"/> Home Infusion Center | Phone: _____ | Address: _____ | |
| Agency Name: _____ | | Phone: _____ Fax: _____ | |
| <input type="checkbox"/> Administration code(s) (CPT): _____ | | TIN: _____ PIN: _____ | |
| Address: _____ | | | |
| E. PRODUCT INFORMATION | | | |
| Request is for MIRCERA (methoxy polyethylene glycol-epoetin beta) | | Dose: _____ | Frequency: _____ |
| F. DIAGNOSIS INFORMATION – Please indicate primary ICD Code and specify any other where applicable. | | | |
| Primary ICD Code: _____ | | Secondary ICD Code: _____ Other ICD Code: _____ | |
| G. CLINICAL INFORMATION – Required clinical information must be completed in its entirety for all precertification requests. | | | |
| For ALL Requests (Clinical documentation required for all requests): | | | |
| <input type="checkbox"/> Yes <input type="checkbox"/> No Does the patient have a documented diagnosis of anemia due to chronic kidney disease (CKD)? | | | |
| <input type="checkbox"/> Yes <input type="checkbox"/> No Will the requested drug be used concomitantly with other erythropoiesis stimulating agents (ESAs)? | | | |
| <input type="checkbox"/> Yes <input type="checkbox"/> No Has the patient received erythropoiesis stimulating agent (ESA) therapy in the previous month (within 30 days of request)? | | | |
| For Initiation Requests (clinical documentation required for all requests): | | | |
| <input type="checkbox"/> Yes <input type="checkbox"/> No Does the patient have a contraindication, intolerance or ineffective response to Retacrit? | | | |
| <input type="checkbox"/> Yes <input type="checkbox"/> No Does the patient have a contraindication, intolerance or ineffective response to Aranesp? | | | |
| <input type="checkbox"/> Yes <input type="checkbox"/> No Has the patient been assessed for iron deficiency anemia? | | | |
| <input type="checkbox"/> Yes <input type="checkbox"/> No Does the patient have adequate iron stores or is receiving iron therapy? | | | |
| → Please identify: <input type="checkbox"/> adequate iron stores <input type="checkbox"/> receiving iron therapy | | | |
| Please indicate the patient's pretreatment hemoglobin (Hgb) level (exclude values due to a recent transfusion): _____ Date of test: ____ / ____ / ____ | | | |
| For Continuation Requests (clinical documentation required for all requests): | | | |
| <input type="checkbox"/> Yes <input type="checkbox"/> No Has the patient completed at least 12 weeks of erythropoiesis stimulating agent (ESA) therapy? | | | |
| → Please indicate the number of weeks completed: _____ | | | |
| <input type="checkbox"/> Yes <input type="checkbox"/> No At any time since the patient started ESA therapy, has the patient's Hgb increased by 1 g/dL or more? | | | |
| Please indicate the patient's current hemoglobin (Hgb) level (exclude values due to a recent transfusion): _____ | | | |
| Date of test: ____ / ____ / ____ | | | |

Continued on next page



**MIRCERA® (methoxy polyethylene glycol-epoetin beta) Medication
Precertification Request**

Page 2 of 2

(All fields must be completed and legible for Precertification Review.)

Aetna Precertification Notification

Phone: 1-866-752-7021

FAX: 1-888-267-3277

For Medicare Advantage Part B:

Phone: 1-866-503-0857

FAX: 1-844-268-7263

| | | | |
|--------------------|-------------------|---------------|-------------|
| Patient First Name | Patient Last Name | Patient Phone | Patient DOB |
|--------------------|-------------------|---------------|-------------|

H. ACKNOWLEDGEMENT

Request Completed By (Signature Required): _____ **Date:** ____ / ____ / ____

Any person who knowingly files a request for authorization of coverage of a medical procedure or service with the intent to injure, defraud or deceive any insurance company by providing materially false information or conceals material information for the purpose of misleading, commits a fraudulent insurance act, which is a crime and subjects such person to criminal and civil penalties.

The plan may request additional information or clarification, if needed, to evaluate requests.